Company profile AGEN

Agenus Inc
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system... to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody Show More
Quarter analysis & expected interestLast update: February 08 2024 13:28:43.

After 39 days of this quarter the interest is at 78.0. Based on that we can calculate that during remaining 52 days it will total up to 182.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019137
136
-0.7% QoQ
149
9.6% QoQ
167
12.1% QoQ
2020 209
52.6% YoY 25.1% QoQ
249
83.1% YoY 19.1% QoQ
291
95.3% YoY 16.9% QoQ
219
31.1% YoY -24.7% QoQ
2021 655
213.4% YoY 199.1% QoQ
583
134.1% YoY -11.0% QoQ
395
35.7% YoY -32.2% QoQ
378
72.6% YoY -4.3% QoQ
2022 229
-65.0% YoY -39.4% QoQ
189
-67.6% YoY -17.5% QoQ
204
-48.4% YoY 7.9% QoQ
174
-54.0% YoY -14.7% QoQ
2023 230
0.4% YoY 32.2% QoQ
214
13.2% YoY -7.0% QoQ
238
16.7% YoY 11.2% QoQ
219
25.9% YoY -8.0% QoQ
2024 78
-66.1% YoY -64.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Agenus search interestLast update: February 08 2024 13:28:42.
Correlation coefficient between keyword and revenue is -0.01
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 13:28:43.

The average 5 years interest of Agenus was 20.47 per week.
The last year interest of Agenus compared to the last 5 years has changed by -17.24%.
The interest for Agenus is significantly decreasing.
The last year interest is quite higher compared to 5 years ago. It has increased by 29.51%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus immunotherapy to provide analysis

Correlation between past revenue and Agenus immunotherapy search interest

There is not enough data for Agenus immunotherapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus immunotherapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus cancer treatment to provide analysis

Correlation between past revenue and Agenus cancer treatment search interest

There is not enough data for Agenus cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus clinical trials to provide analysis

Correlation between past revenue and Agenus clinical trials search interest

There is not enough data for Agenus clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 13:28:47.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Agenus stock price expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201975
88
17.3% QoQ
33
-62.5% QoQ
179
442.4% QoQ
2020 67
-10.7% YoY -62.6% QoQ
147
67.0% YoY 119.4% QoQ
207
527.3% YoY 40.8% QoQ
183
2.2% YoY -11.6% QoQ
2021 433
546.3% YoY 136.6% QoQ
433
194.6% YoY 0.0% QoQ
277
33.8% YoY -36.0% QoQ
161
-12.0% YoY -41.9% QoQ
2022 49
-88.7% YoY -69.6% QoQ
115
-73.4% YoY 134.7% QoQ
82
-70.4% YoY -28.7% QoQ
198
23.0% YoY 141.5% QoQ
2023 104
112.2% YoY -47.5% QoQ
130
13.0% YoY 25.0% QoQ
79
-3.7% YoY -39.2% QoQ
139
-29.8% YoY 75.9% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Agenus stock price search interestLast update: February 08 2024 13:28:47.
Correlation coefficient between keyword and revenue is 0.09
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 13:28:48.

The average 5 years interest of Agenus stock price was 12.18 per week.
The last year interest of Agenus stock price compared to the last 5 years has changed by -39.08%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 2.91%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus CEO to provide analysis

Correlation between past revenue and Agenus CEO search interest

There is not enough data for Agenus CEO to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus CEO to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 13:28:56.

After 39 days of this quarter the interest is at 43.0. Based on that we can calculate that during remaining 52 days it will total up to 100.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019124
25
-79.8% QoQ
183
632.0% QoQ
215
17.5% QoQ
2020 228
83.9% YoY 6.0% QoQ
219
776.0% YoY -3.9% QoQ
109
-40.4% YoY -50.2% QoQ
148
-31.2% YoY 35.8% QoQ
2021 327
43.4% YoY 120.9% QoQ
149
-32.0% YoY -54.4% QoQ
231
111.9% YoY 55.0% QoQ
137
-7.4% YoY -40.7% QoQ
2022 145
-55.7% YoY 5.8% QoQ
156
4.7% YoY 7.6% QoQ
90
-61.0% YoY -42.3% QoQ
49
-64.2% YoY -45.6% QoQ
2023 111
-23.4% YoY 126.5% QoQ
141
-9.6% YoY 27.0% QoQ
26
-71.1% YoY -81.6% QoQ
107
118.4% YoY 311.5% QoQ
2024 43
-61.3% YoY -59.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Agenus news search interestLast update: February 08 2024 13:28:56.
Correlation coefficient between keyword and revenue is 0.13
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 13:28:58.

The average 5 years interest of Agenus news was 11.35 per week.
The last year interest of Agenus news compared to the last 5 years has changed by -31.72%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -39.92%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus partnerships to provide analysis

Correlation between past revenue and Agenus partnerships search interest

There is not enough data for Agenus partnerships to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus partnerships to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus pipeline to provide analysis

Correlation between past revenue and Agenus pipeline search interest

There is not enough data for Agenus pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Agenus upcoming events to provide analysis

Correlation between past revenue and Agenus upcoming events search interest

There is not enough data for Agenus upcoming events to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Agenus upcoming events to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for AGEN
Earnings date: 2024-03-12 After close
Company name: Agenus Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-11T12:45:00Z

BusinessWire
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

2026-05-04T20:30:00Z

BusinessWire
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

2026-04-21T14:00:00Z

BusinessWire
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

2026-04-21T12:00:00Z

BusinessWire
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

2026-04-17T20:43:00Z

BusinessWire
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

2026-04-03T11:30:00Z

BusinessWire
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

2026-04-01T11:30:00Z

BusinessWire
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

2026-03-26T20:52:00Z

BusinessWire
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

2026-03-17T20:40:00Z

BusinessWire
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

2026-03-16T11:30:00Z

BusinessWire
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

2026-03-10T11:30:00Z

BusinessWire
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

2026-03-04T21:30:00Z

BusinessWire
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

2026-02-19T20:15:00Z

BusinessWire
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

2026-02-09T18:00:00Z

BusinessWire
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

2026-01-15T08:30:00-05:00

PR Newswire
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.